Insulet [PODD] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Insulet
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Insulet wins in 5 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Insulet | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 99.95 | 16.56 | Abbott Laboratories |
| Price-to-Book Ratio | 15.77 | 4.54 | Abbott Laboratories |
| Debt-to-Equity Ratio | 95.68 | 26.50 | Abbott Laboratories |
| PEG Ratio | -1.13 | 0.45 | Insulet |
| EV/EBITDA | 49.09 | 20.62 | Abbott Laboratories |
| Profit Margin (TTM) | 10.01% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 18.66% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 18.66% | 19.73% | Abbott Laboratories |
| Return on Equity | 19.18% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 7.75% | 6.62% | Insulet |
| Free Cash Flow (TTM) | $296.30M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 78.76% | 17.64% | Insulet |
| Price-to-Sales Ratio (TTM) | 9.78 | 5.33 | Abbott Laboratories |
| Enterprise Value | $23.36B | $236.19B | Abbott Laboratories |
| EV/Revenue Ratio | 9.90 | 5.48 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 69.67% | 56.44% | Insulet |
| Revenue per Share (TTM) | $34 | $25 | Insulet |
| Earnings per Share (Diluted) | $3.28 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.35 | 0.71 | Abbott Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Insulet vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Insulet | 0.89% | 2.96% | 15.83% | 3.04% | 16.68% | 28.78% |
| Abbott Laboratories | 0.45% | 0.64% | 5.46% | 0.83% | -1.75% | 16.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Insulet | 78.76% | 23.81% | 54.32% | 1,013.33% | 2,316.14% | 2,078.99% |
| Abbott Laboratories | 17.64% | 30.10% | 19.66% | 188.07% | 454.45% | 517.75% |
Performance & Financial Health Analysis: Insulet vs Abbott Laboratories
| Metric | PODD | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $23.08B | $229.74B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 680,330 | 5,726,190 |
| 90 Day Avg. Volume | 639,633 | 7,154,530 |
| Last Close | $330.77 | $132.59 |
| 52 Week Range | $180.31 - $334.18 | $110.86 - $141.23 |
| % from 52W High | -1.02% | -6.12% |
| All-Time High | $335.91 (May 01, 2023) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -1.53% | -7.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.33% | 0.07% |
| Quarterly Earnings Growth | -0.88% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.32% |
| Operating Margin (TTM) | 0.19% | 0.20% |
| Return on Equity (TTM) | 0.19% | 0.31% |
| Debt to Equity (MRQ) | 95.68 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $20.78 | $29.05 |
| Cash per Share (MRQ) | $15.93 | $4.18 |
| Operating Cash Flow (TTM) | $516.20M | $9.04B |
| Levered Free Cash Flow (TTM) | $112.66M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Insulet vs Abbott Laboratories
| Metric | PODD | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 99.95 | 16.56 |
| Forward P/E | 84.72 | 25.58 |
| PEG Ratio | -1.13 | 0.45 |
| Price to Sales (TTM) | 9.78 | 5.33 |
| Price to Book (MRQ) | 15.77 | 4.54 |
| Market Capitalization | ||
| Market Capitalization | $23.08B | $229.74B |
| Enterprise Value | $23.36B | $236.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.90 | 5.48 |
| Enterprise to EBITDA | 49.09 | 20.62 |
| Risk & Other Metrics | ||
| Beta | 1.35 | 0.71 |
| Book Value per Share (MRQ) | $20.78 | $29.05 |
Financial Statements Comparison: Insulet vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PODD | ABT |
|---|---|---|
| Revenue/Sales | $569.00M | $10.36B |
| Cost of Goods Sold | $160.00M | $4.47B |
| Gross Profit | $409.00M | $5.89B |
| Research & Development | $59.60M | $716.00M |
| Operating Income (EBIT) | $88.80M | $1.69B |
| EBITDA | $118.50M | $2.66B |
| Pre-Tax Income | $48.10M | $1.78B |
| Income Tax | $12.70M | $453.00M |
| Net Income (Profit) | $35.40M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PODD | ABT |
|---|---|---|
| Cash & Equivalents | $1.28B | $6.53B |
| Total Current Assets | $2.33B | $23.15B |
| Total Current Liabilities | $520.40M | $13.00B |
| Long-Term Debt | $1.61B | $12.74B |
| Total Shareholders Equity | $1.33B | $49.06B |
| Retained Earnings | $75.70M | $47.72B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PODD | ABT |
|---|---|---|
| Operating Cash Flow | $81.00M | $1.42B |
| Capital Expenditures | N/A | $-484.00M |
| Free Cash Flow | $48.10M | $933.00M |
| Debt Repayment | $-182.70M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | PODD | ABT |
|---|---|---|
| Shares Short | 1.75M | 18.33M |
| Short Ratio | 3.03 | 2.44 |
| Short % of Float | 0.04% | 0.01% |
| Average Daily Volume (10 Day) | 680,330 | 5,726,190 |
| Average Daily Volume (90 Day) | 639,633 | 7,154,530 |
| Shares Outstanding | 70.20M | 1.73B |
| Float Shares | 70.08M | 1.73B |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 1.02% | 0.81% |
Dividend Analysis & Yield Comparison: Insulet vs Abbott Laboratories
| Metric | PODD | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |